PM
AMPE

Prosight Management’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Prosight Management’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-371
Closed -$378K – 39
2018
Q1 		$378K Buy
+371
New +$311K 0.24% 31

Other funds holding AMPE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $108M AUM 54.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return

Prosight Management's AMPE Position: Q2 2018 in Review

Prosight Management sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q2 2018, closing a stake of 371 shares — an estimated $378K sold.

Prosight Management first reported a position in AMPE in Q1 2018 and held it in 1 quarter. The position peaked at $378K in Q1 2018. 86 funds tracked by Wall St. Rank hold AMPE as of Q2 2018.

  • Prosight Management reported no remaining Ampio Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Prosight Management sold 371 Ampio Pharmaceuticals Inc. shares in Q2 2018, an estimated $378K.
  • Prosight Management first reported a position in Ampio Pharmaceuticals Inc. in Q1 2018 and held it in 1 quarter.
  • Prosight Management's Ampio Pharmaceuticals Inc. position peaked at $378K in Q1 2018.
  • 86 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q2 2018.

Based on Prosight Management's 13F filing for Q2 2018, filed 14 Aug 2018.